2022.07.06
I-Mab to Host 2022 R&D Day
I-Mab today announced that it will host its 2022 Research and Development Day on July 20, 2022.
2022.06.23
I-Mab Receives Top Rankings in Five Categories by Institutional Investor
I-Mab today announced that it was ranked among the top companies in five different categories by leading global financial publication Institutional Investor.
2022.06.15
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
I-Mab today announced two assets the Company has licensed from partner MorphoSys are advancing globally through new license agreements.
2022.05.31
I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency
I-Mab announced the completion of patient enrollment in a Phase 3 clinical trial of eftansomatropin alfa, which is being investigated as a weekly treatment for PGHD in China.
2022.05.27
I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
I-Mab today announced preliminary data of its ongoing Phase 2 clinical trial with uliledlimab and its global clinical development plan.
2022.05.19
I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
The Company will hold a call with investors at 8 a.m. EST on May 27th.
2022.05.05
I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act
I-Mab today provided updates on its status under the Holding Foreign Companies Accountable Act.
2022.04.28
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
I-Mab announced today two key appointments of Mr. Richard Yeh as Chief Operating Officer and Dr. John Hayslip as Chief Medical Officer.
2022.03.31
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
I-Mab today announced that the Company’s key shareholders and its senior management team have voluntarily entered into a 180-days lock-up period commencing from March 31, 2022.
2022.03.29
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
I-Mab today announced financial results for the 12 months ended December 31, 2021, and provided key business updates.